Company intelligence / Profile preview

Arnold

Ownership: Private
Development stage: Other

Overview

Arnold is a biotechnology company focused on developing next-generation glucocorticoid receptor modulators. The company aims to create therapies that provide the potent anti-inflammatory benefits of traditional steroids while minimizing the severe side effects typically associated with long-term glucocorticoid use. By leveraging structural biology and medicinal chemistry, Arnold is designing selective ligands that target specific signaling pathways of the glucocorticoid receptor. Their lead programs are currently in the pre-clinical stage, targeting a range of inflammatory and autoimmune conditions.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Arnold.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arnold.

Explore the full profile